MicrofluidX develops precision microfluidic systems that enhance process control and scalability in cell bioprocessing, significantly lowering operational costs. Their technology improves the consistency and yield of cell cultures in biomanufacturing, addressing inefficiencies in traditional methods.
Funding
Funding not disclosed
Founders
Product
Problem
Cell and gene therapies hold immense promise, but their development and manufacturing are often hindered by inefficient and inconsistent bioprocessing methods. Traditional cell culture techniques lack the scalability and precise control needed for cost-effective production of engineered cells. This limits patient access to these potentially life-saving treatments.
Solution
MFX is developing the Cyto Engine, an automated bioprocessing platform that combines scalable microfluidics with advanced analytics to accelerate cell and gene therapy development and manufacturing. The Cyto Engine aims to improve the consistency and efficiency of cell cultures, enabling more cost-effective and scalable production of engineered cells. By integrating automated bioprocessing with powerful analytics and data management, MFX seeks to unlock access to cell and gene therapies.
Target Audience
The primary target audience includes cell and gene therapy developers and manufacturers seeking to improve the efficiency, scalability, and consistency of their bioprocessing workflows.
Features
- Scalable, automated microfluidic bioprocessing for enhanced control over cell culture conditions
- Integrated analytics and data management for real-time monitoring and optimization of bioprocesses
- Streamlined workflow for cell and gene therapy development and manufacturing